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One-pot RAFT and fast polymersomes assembly:
a ‘beeline’ from monomers to drug-loaded
nanovectors†
F. Mastrotto,a A. F. Breen,a G. Sicilia,a S. Murdan,b A. D. Johnstone,c G. E. Marsh,a
C. Grainger-Boultby,a N. A. Russell,c C. Alexandera and G. Mantovani*a
Rapid and simple routes to functional polymersomes are increasingly needed to expand their clinical or
industrial applications. Here we describe a novel strategy where polymersomes are prepared through an
in-line process in just a few hours, starting from simple acrylate or acrylamide monomers. Using Perrier’s
protocol, well-deﬁned amphiphilic diblock copolymers formed from PEG acrylate (mPEGA480), 2-(acryl-
oyloxy)ethyl-3-chloro-4-hydroxybenzoate (ACH) or 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate
(CHB), have been synthesised by RAFT polymerisation in one-pot, pushing the monomer conversion for
each block close to completion (≥94%). The reaction mixture, consisting of green biocompatible solvents
(ethanol/water) have then been directly utilised to generate well-deﬁned polymersomes, by simple can-
nulation into water or in a more automated process, by using a bespoke microﬂuidic device. Terbinaﬁne
and cyanocobalamine were used to demonstrate the suitability of the process to incorporate model
hydrophobic and hydrophilic drugs, respectively. Vesicles size and morphology were characterised by
DLS, TEM, and AFM. In this work we show that materials and experimental conditions can be chosen to
allow facile and rapid generation drug-loaded polymersomes, through a suitable in-line process, directly
from acrylate or acrylamide monomer building blocks.
Introduction
Polymersomes1 are vesicular assemblies formed from amphi-
philic block copolymers, which have rapidly emerged as an
important class of nanomaterials, with range of potential appli-
cations which include drug delivery, diagnostics and
bioimaging.2–4 To date, polymersomes have been the subject of
over 500 papers, with at least 11 patents filed within the last two
years.5 Compared to phospholipid vesicles, polymersomes typi-
cally possess improved membrane stability, as well as superior
tuneability of surface chemistry and structural parameters.6
An increasingly large area of research is focussed on the
use of polymersomes as drug nanovectors in drug delivery.7–10
Recently, Battaglia and coworkers showed delivery of an IgG
model cargo to the Central Nervous System (CNS) parenchyma
and CNS cells mediated by poly(2-diisopropylamino)ethyl
methacrylate)-based pH-responsive polymersomes functiona-
lized with LRP-1-targeting Angiopep-2 and Rabies Virus
Glycoprotein (RVG) peptide ligands to facilitate transport
through the blood–brain barrier.11
Polymersomes have also been utilised to create nanosized
reactors, where entrapped (bio)molecules – e.g. enzymes – are
part of multicompartmental arrangements mimicking those
found in cell organelles. In an early work Meier and coworkers
incorporated β-lactamase within PDMS-PMOXA triblock co-
polymer vesicles.12 The introduction of a channel-forming
protein from the outer cell wall of Gram-negative bacteria
(OmpF) into the vesicle membrane allowed passive transport
of ampicillin, an enzyme substrate, which was converted in the
polymersome aqueous lumen into ampicillinoic acid.
Lecommandoux and van Hest engineered multicompartimen-
talised polymersomes-in-polymersomes systems, mimicking
artificial cells and cell organelles.13 These studies, in conjunc-
tion with the potential for self-propulsion,14 make polymer-
somes ideal candidates for the development of polymeric
protocells.15,16
In terms of their manufacturing, polymersomes are often
assembled from amphiphilic block copolymers synthesised
through long synthetic procedures – typically at least two
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sequential polymerisations, requiring purification of both
polymer intermediates and final amphiphilic macromolecules
from unreacted monomers and traces of other low molecular
weight impurities. Importantly, polymerisation reactions often
need to be stopped at moderate monomer conversions to
ensure high proportion of chain-end fidelity, which is required
for subsequent polymer chain-extension.17–19
In addition to being not fully eﬃcient, this approach invari-
ably results in waste of functional monomers utilised for the
polymerisation step, which is undesirable especially when
these are particularly expensive, not commercially available, or
both. Finally, the processes for the assembly of polymersomes
are not always trivial.20 Although a range of techniques have
been developed,21 most methods still suﬀer from low reprodu-
cibility and poor scalability, which may complicate industrial
application of polymersomes.6 Whilst chemists are increas-
ingly focussing on developing more eﬃcient and greener
chemical transformations – i.e. as described by Sharpless and
coworkers’ click chemistry philosophy – one could envisage
that analogous approaches could be applied not only to indi-
vidual chemical reactions, but also to entire processes. A clear
move in this direction is the work on polymerization-induced
self-assembly (PISA) by Armes’ group and others,22–30 where
block copolymers nano-objects can be assembled with predict-
able shape and size during the polymerisation process, by judi-
cious choice of monomers and variation of polymer physico-
chemical characteristics (e.g. packing parameter P).31
In the present work we aimed to develop a route to self-
assembled drug nanovectors which would complement the
range of applications inherent to PISA. In this case, drug-
loaded nanovesicles are engineered by sequential and quanti-
tative polymerisation of appropriate monomers in one pot, fol-
lowed by self-assembly of the resulting amphiphilic block copo-
lymers into vesicles, by directly adding the final reaction
mixture to a suitable aqueous phase (Chart 1). Key advantages
of this approach include the avoidance of intrinsically ineﬃ-
cient purifications of polymer intermediates, the potential for
incorporating a wide range of drugs – including those not com-
patible with radical polymerisation conditions, and, similarly to
PISA, facile assembly of nanovectors directly from the polymeri-
sation solution, but without having to remove excess unreacted
monomers.
For the polymerisation step, recent studies by Perrier and
co-workers showed that well-defined multiblock copolymers
can be obtained by RAFT polymerisation in one pot by sequen-
tial and quantitative polymerisation of suitable monomers in
only a few hours18,32,33 or even minutes.34 The monomers were
selected based on previous studies, where we showed that
block copolymers based on novel pH-responsive monomers
bearing substituted aromatic alcohols could be eﬀectively
assembled into well-defined nanovesicles, whilst incorporating
specific drugs with high eﬃciency.35,36
Experimental
Materials
Terbinafine free base was extracted from a basic aqueous solu-
tion of terbinafine hydrochloride (Sigma-Aldrich ≥98%) with
dichloromethane (see ESI†). VA-044 was purchased from Wako
Pure Chemical Industries Ltd. All the other solvents and
reagents were purchased from Sigma-Aldrich or Fisher
Scientific and used as received. Spectra/Por 8 kDa MWCO and
SnakeSkin 3.5 kDa MWCO dialysis tubing were obtained from
Fisher Scientific and VWR International, respectively.
Cellulose membranes (0.45 and 0.22 μm) were purchased from
Merck Millipore. 1H–13C HSQC NMR experiments were carried
out to facilitate peaks assignment. Yields were not optimized.
Synthesis of 2-(acryloyloxy)ethyl 3-chloro-4-hydroxybenzoate
(ACH, 2) and 2-(3-chloro-4-hydroxybenzamido)ethyl acrylate
(CHB, 3). The synthesis of the acrylic ACH (2) and acrylamide
CHB (3) monomers was carried out by reaction of 3-chloro-4-
hydroxybenzoic acid with 2-hydroxyethyl acrylate (HEA) or
N-hydroxyethyl acrylamide (HEAM), respectively. The typical
procedure is described here for the synthesis of ACH (2)
monomer. A solution of DCC (17.1 g, 82.7 mmol) in anhydrous
Chart 1 In line engineering of mPEGA12a-b-ACH36 or mPEGA12a-b-CHB36 polymeric vesicles via one-pot RAFT and in line post-polymerisation
assembly.
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CH2Cl2 (100 mL) was added dropwise and under stirring to a
solution of 3-chloro-4-hydroxybenzoic acid (10.0 g, 55.1 mmol)
and DMAP (0.256 g, 2.09 mmol) dissolved in 2-hydroxyethyl
acrylate (63.3 mL, 551 mmol), over 30 minutes The reaction
mixture was stirred at room temperature for 16 hours, and the
resulting dicyclohexylurea (DCU) precipitate was removed by
filtration. The solvent was removed under reduced pressure,
the resulting residue dissolved in MeOH, and the monomer
precipitated in deionized water at pH 5.0 to remove most of
the excess of HEA. The precipitate was isolated by centrifu-
gation, redissolved in CH2Cl2 (ca. 150 mL) and the resulting
solution was dried over MgSO4, filtered, and the solvent
removed under reduced pressure. The crude product was puri-
fied by flash chromatography (silicagel 60, 35–70 µm, CH2Cl2/
EtOAc 9.5 : 0.5 vol/vol). Evaporation of the solvent from the
relevant fractions yielded the desired monomer ACH (2) as a
white solid. CHB (3) was synthesised using THF instead of
CH2Cl2 as the solvent and was purified by flash chromato-
graphy (silicagel 60, 35–70 µm, eluents CH2Cl2/EtOAc, gradient
9.5 : 0.5 to 1 : 1, vol/vol).
ACH (2). 13.6 g, 50.1 mmol, Yield: 90.9%. ESI-TOF mass
spectrometry: expected m/z for [M − H]− 269.02, found 269.02
Da FT-IR: ν 3330, 2937, 1716, 1686, 1601, 1580, 1455, 1411,
1363, 1251, 1186, 1072, 1023, 966, 936, 897, 833, 810, 760,
709 cm−1. 1H NMR (400 MHz, CDCl3, δ, ppm): 4.47–4.55 (m,
4H, CH2), 5.88 (dd, J = 10.4, 1.4 Hz, 1H, CHvCHH), 6.14 (dd,
J = 17.3, 10.4 Hz, 1H, CHvCH2), 6.42 (dd, J = 17.3, 1.4 Hz, 1H,
CHvCHH), 7.07 (d, J = 8.6 Hz, 1H, CH aromatic), 7.9 (dd, J =
8.5, 2.0 Hz, 1H, CH aromatic), 8.03 (d, J = 2.0 Hz, 1H, CH aro-
matic). 13C {1H} NMR (100 MHz, CDCl3, δ, ppm): 62.43 (1C,
CH2O), 63.00 (1C, CH2O), 116.24 (1C, C aromatic), 120.23 (1C,
C aromatic), 123.29 (1C, C aromatic), 128.08 (1C, CHvCH2),
130.52 (1C, C aromatic, CH), 131.21 (1C, C aromatic), 131.65
(1C, CH2vCH), 155.76 (1C, C aromatic), 165.13 (1C, CvO),
166.03 (1C, CvO).
CHB (3). 3.00 g, 11.2 mmol, Yield: 40.7%. ESI-TOF mass
spectrometry: expected m/z for [M − H]− 268.04, found 267.92
Da FT-IR: ν 3328, 3139, 2938, 2111, 1690, 1646, 1617, 1596,
1527, 1489, 1386, 1357, 1323, 1294, 1265, 1238, 1145, 1118,
1053, 972, 890, 872, 834, 804, 669 cm−1. 1H NMR (400 MHz,
MeOD, δ, ppm): 3.64 (t, J = 5.4 Hz, 2H, CH2N), 4.36 (t, J = 5.4
Hz, 2H, OCH2), 5.66 (dd, 1H, J = 8.3, 3.7 Hz, 1H, CHvCHH),
6.22 (dd, 1H, J = 17.1, 3.7 Hz, CHvCHH), 6.27 (dd, 1H, J =
17.1, 8.3 Hz, CHvCH2), 6.95 (d, 1H, J = 8.5 Hz, CH aromatic),
7.82 (m, 1H, CH aromatic), 7.98 (m, 1H, CH aromatic). 13C
{1H} NMR (100 MHz, MeOD, δ ppm): 39.55 (1C, CH2NH), 64.51
(1C, CH2O), 117.1 (1C, C aromatic, CH), 121.8 (1C, C aromatic,
CCl), 123.18 (1C, C aromatic, CCO), 126.96 (1C, CH2vC),
130.95 (1C, C aromatic, CH), 131.83, (1C, CHvCH2), 132.79
(1C, C aromatic, CH), 159.16 (1C, C aromatic, C–OH), 166.83
(1C, CvO), 168.45 (1C, CvO).
General one-pot polymerisation procedure: synthesis of
mPEGA12a-b-ACH36 (6), block copolymers
The synthesis of the pH-responsive block copolymers was per-
formed via an adaptation of the one-pot RAFT polymerisation
strategy described by Perrier and co-workers.18 Monomer con-
version after each step are shown in Table 1.
mPEGA12a-b-ACH36. mPEGA(480) (440 µL, 1.00 mmol) and
MHP RAFT Agent (19.9 mg, 83.3 µmol, synthesis and charac-
terisation are reported in the ESI†) were placed in a tube
equipped with a magnetic follower and EtOH (100 µL) was
added (NOTE: the monomer : solvent vol : vol ratio was found
to be critical to achieve the required degree of control over the
chain end-group fidelity, in agreement with what described by
Perrier and co-workers.18,32–34 Here a 2.0 M monomer concen-
tration was used in all cases, and when liquid monomers were
used, their volume was taken into account when calculating
the solvent required to achieve the required monomer concen-
tration). The tube was sealed with a rubber septum, placed in
an ice bath, stirred for 5 min to allow temperature equili-
bration, deoxygenated by gentle Argon bubbling for
15 minutes, and finally placed in an oil bath pre-heated at
70 °C. 0.332 µmol of VA-044 (59 µL of a 1.82 mg mL−1 deoxyge-
nated stock solution in HPLC-grade water) were then added via
gas-tight syringe to the reaction tube (t0). After 2 h near-quanti-
tative conversion of mPEGA(480) into mPEGA12a macro-CTA
was confirmed by 1H NMR of an aliquot taken from the reac-
tion mixture, which was also analysed by SEC (DMF + 0.1%
LiBr as the mobile phase) to estimate Mn and polydispersity
index of the mPEGA12a polymer intermediate.
In a separate Schlenk tube ACH monomer (803 mg,
2.96 mmol) was dissolved in 1.5 mL of water : EtOH (1 : 2 vol/
vol); the tube was placed in an ice bath, stirred for 5 min to
allow temperature equilibration, and deoxygenated by gentle
Argon bubbling for 15 minutes. This solution was then cannu-
Table 1 Characterization and [M]/[CTA]/[I] ratios utilised for the synthesis of mPEGA12 macro-CTAs and mPEGA12a-b-ACH36, mPEGA12b-b-CHB36
block copolymers
Polymer Code [M]/[CTA]/[I] Conv.%a Mn, NMR (kDa) Mn, SEC (kDa) Đ
mPEGA12a 4 12 : 1 : 0.004 95 5.7 6.5
c 1.05c
mPEGA12b 5 12 : 1 : 0.004 98 5.3 6.1
d 1.13d
mPEGA12a-b-ACH36 6 36 : 1 : 0.02 94 15.5
b 14.9c 1.18c
mPEGA12b-b-CHB36 7 36 : 1 : 0.034 95 15.2
b 15.1d 1.17d
aObtained from 1H NMR analysis. bNumber of repeating unit of ACH or CHB monomers, DPACH and DPCHB respectively, were calculated by
1H NMR by comparing the integral of monomer aromatic proton peak at 6.93 (I6.93) ppm, and the methoxy peak of mPEGA repeating units
at 3.23 ppm (I3.23) set as 3. DPACH (or DPCHB) = 12 × (I6.93/(I3.23/3). Mn, NMR was calculated as: (−DPACH (or DPCHB) × MWmonomer) + Mn, macroCTA).
cObtained from SEC analysis in DMF + 0.1% LiBr (PMMA standards). dObtained from SEC analysis in CHCl3 (polystirene standards).
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lated under Argon into the polymerisation tube containing
mPEG12a macro-CTA, and the resulting solution heated at
70 °C under stirring. The polymerisation was started by
addition of a previously degassed VA-044 solution in HPLC-
grade water (96 µL, 0.54 µmol) via gas-tight syringe. After 2 h
at 70 °C ACH monomer conversion was checked by 1H NMR in
DMSO-d6. Three sequential additions of degassed fresh
initiator solution (96 µL), each followed by 2 h stirring at 70 °C
were performed, until conversion finally reached 94%.
mPEGA12b-b-CHB36 (7). The synthesis of mPEGA12b-b-CHB36
block copolymer was performed as described above, but five
sequential additions of degassed VA-044 initiator solution
(96 µL, 0.54 µmol) were performed to reach 99% monomer
conversion.
mPEGA12a (4). Conversion = 95% Mn, theor = 5.71 kDa;
DPtheor = 11.4, Mn (GPC, DMF) = 6.49 kDa; Đ(GPC, DMF) = 1.05.
mPEGA12b (5). Conversion = 97% Mn, theor = 5.83 kDa;
Mn (GPC, CHCl3) = 5.3 kDa; DP = 11.6; Đ(GPC, CHCl3) = 1.13.
mPEGA12a-b-ACH36 (6). Conversion = 94%; Mn, theor =
14.92 kDa; Mn (GPC, DMF) = 14.9 kDa; DP 2
nd block = 36;
Đ(GPC, DMF) = 1.18.
mPEGA12b-b-CHB36 (7). Conversion = 99%; Mn, theor =
14.97 kDa; Mn (GPC, DMF) = 15.07 kDa; DPtheor 2
nd block = 36;
Đ(GPC, DMF) = 1.17.
In line assembly of polymersomes
In a typical procedure, at the end of the polymerisation run
the reaction mixture was diluted with EtOH to a final polymer
concentration of 35 mg mL−1 while maintaining the tempera-
ture at 40 °C, under stirring. The resulting polymer solution
was then directly cannulated into DI water (EtOH : H2O 1 : 35
vol/vol, final polymer concentration 1.0 mg mL−1).
The polymersomes formation occurred instantaneously, as
confirmed by DLS. To remove the residual ethanol, the vesicles
suspension was transferred into a dialysis bag (3.5 kDa
MWCO) and dialyzed against 5 L of DI water for 4 hours at
room temperature with at least 4 water exchanges.
Alternatively, the beaker containing the polymersomes suspen-
sions were left to stir overnight to allow the organic solvent to
evaporate. Samples were analysed by DLS and TEM.
Polymersomes assembly by nanoprecipitation
For comparative purposes, assembly of polymersomes was also
performed by nanoprecipitation on purified block copolymers.
Briefly, at the end of the polymerisation reaction mixtures were
diluted with acetone (10 mL) and precipitated twice in pet-
roleum ether (200 mL). 5 mg mL−1 polymer solutions were
then prepared in DMSO, and diluted to 1 mg mL−1 by addition
of either water or PBS. To remove the organic solvent, vesicles
suspensions were transferred into a dialysis bag (3.5 kDa
MWCO) and dialyzed against 5 L of DI water or PBS for
24 hours at room temperature with at least 4 solvent
exchanges. Vesicles size was analysed by DLS and, for samples
prepared in PBS, by atomic force microscopy (AFM).
Polymersome assembly via a microfluidic device
Polymersomes were also assembled using a bespoke microflui-
dic device. Two syringes feeding into the device were driven
simultaneously by a dual Cole-Palmer 789210C syringe pump.
A 10 mL syringe (internal diameter 15.8 mm) delivered at 12
times the volume flow rate of the 1 mL syringe (internal dia-
meter 4.6 mm). The 1 mL syringe was maintained at 50 °C by a
heating jacket and contained an ethanolic solution (12 mg
mL−1) of mPEGA12b-b-CHB36. This solution was injected into
the device at a flow rate of 10 µL min−1 (Flow A, Fig. 4), via a
27G needle (internal diameter 0.21 mm) inserted into a PTFE
tube (ID 0.5 mm). The tube ensured a leak-free fit while allow-
ing the needle to be removed as required. Concurrently, water
was introduced in the device via the 10 mL syringe, through
another ID 0.5 mm PTFE tube, at a flow rate of 120 µL min−1
(Flow B, Fig. 4). The tubes led to a mixing junction placed on a
60 °C hotplate, and the mixed flow (Flow C, 130 µL min−1,
Fig. 4) excited the device to a collection vial via an ID 1 mm
tube. The experiment was repeated twice and at least 3
diﬀerent samples were collected and analysed by DLS.
Drug loading procedure
Terbinafine free base and cyanocobalamin co-loaded polymer-
somes were assembled following a procedure analogous to
that described in the “in line assembly of polymersomes”
section. Typically, terbinafine free base (10% w/w drug/
polymer) and cyanocobalamin (10% w/w drug/polymer) were
respectively added to the polymer ethanolic/water solution
and/or the aqueous phase before the assembly procedure. To
remove unentrapped cyanocobalamin and residual organic
solvent the polymersomes suspension was dialysed with 8 kDa
MWCO dialysis membrane against 5 L of DI water, with 4
water exchanges in 5 hours. Unentrapped terbinafine, precipi-
tated after dialysis, was removed by centrifugation (1500 rpm,
5 minutes) followed by filtration through a 0.45 µm mixed
cellulose ester membrane.
Drug loading was then quantified via a RP-HPLC method
(see ESI†). Loading reported for each polymer is the average of
two independent experiments, each prepared and analysed in
triplicate.
Loading Capacity (LC) and Encapsulation Eﬃciency (EE)
were calculated as:
LC ¼ Amount of loadeddrug
Amount of polymer
 100
EE ¼ Amount of loadeddrug
Total amount of drug
 100
Polymersome size analysis
Particles size analyses were carried out at 25 °C by Dynamic
Light Scattering (DLS) using a Zetasizer Nano spectrometer
(Malvern Instruments Ltd) equipped with a 633 nm laser at a
fixed angle of 173°. Samples were kept at constant temperature
(25 °C) during all the experiments. Polymeric vesicles were pre-
pared as described in “in line assembly of polymersomes”, by
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nanoprecipitation or via microfluidic device. Residual EtOH
was removed either by solvent evaporation or by dialysis with a
3.5 kDa MWCO dialysis membrane before analysis. Results are
reported as the z-average. All experiments were performed in
triplicate.
Transmission electron microscopy (TEM)
Transmission Electron Microscopy (TEM) was performed on a
FEI TecnaiTM 12 Biotwin transmission electron microscope.
20 µL of 1 mg mL−1 polymersomes suspension in water were
placed on a carbon coated copper grid. After 5 minutes the
excess of volume was wicked away with filter paper, the
samples were negatively stained with 3% uranyl acetate in dis-
tilled water and analysed. 191 and 207 individual vesicles were
measured from the digitised images for mPEGA12a-b-ACH36
and mPEGA12b-b-CHB36, using imageJ 1.45 analysis software.
Atomic force microscopy (AFM)
Atomic Force Microscopy topography images of mPEGA12a-b-
ACH36 and mPEGA12a-b-CHB36 polymersomes were obtained in
liquid at room temperature using a Bruker Icon FastScan Bio
operating in PeakForce nanomechanical tapping mode in fluid
using ScanA-syst-Fluid + probes (resonant mechanical fre-
quency: 120–180 kHz, spring constant: 0.7 N m−1). Images
were acquired under ScanAsyst auto control using scan rates of
1.60 Hz, with a resolution of 512 × 512 pixels. Small pieces
(0.5 cm × 0.5 cm) of freshly cleaved mica were used as sub-
strates. 10 mM MgCl2 solution was incubated with cleaved
mica for 30 min. Subsequently, the mica was washed with dis-
tilled water and blow-dried under nitrogen stream at room
temperature. Polymersomes prepared by the nanoprecipitation
method followed by dialysis against PBS were diluted with
additional PBS to a final polymer concentration of 500 µg
mL−1 and filtered through a 0.45 µm syringe filter. The diluted
polymersome solution (100 µL) was pipetted on the mica sub-
strate and then imaged. Image data were analysed using
Nanoscope Analysis software (Version 1.5, Bruker).
Results and discussion
In line polymersomes: synthesis of ACH acrylate and CHB
acrylamide-based copolymers mPEGA12a-b-ACH36 and
mPEGA12b-b-CHB36
Accordingly, in this work the required monomers were pre-
pared in one step, by DCC-mediated coupling reaction of
3-chloro-4-hydroxybenzoic acid with (hydroxyethyl)acrylate
(HEA) or (hydroxyethyl)acrylamide (HEAM), to give acrylate
and acrylamide monomers ACH (2) and CHB (3), respectively
(Scheme 1, and ESI, Fig. S5–S8†). Unlike our previous studies
where methacrylates were utilised,35,36 in this work the analo-
gous acrylate/acrylamide monomers, characterised by higher
propagation rate coeﬃcient (Kp),
37,38 required for subsequent
one-pot rapid multiple chain extensions at close to full
monomer conversion, as described by Perrier and co-workers,
were synthesised. To prove the versatility of the strategy develo-
ped in this study, both acrylate and acrylamide monomers
were utilised.
To successfully prepare multiblock copolymers via this one-
pot RAFT process, a number of parameters – e.g. choice of the
solvent, initiator, monomer concentration, temperature and
[CTA]/[I] ratio – are key for maintaining near-perfect chain-end
fidelity, thus ensuring “livingness” of the polymerisation.18
A mixture of water/EtOH was chosen as a suitable “green”
solvent39 for the subsequent polymerisation step. Water is
known to increase the propagation rate coeﬃcient (Kp), and
Scheme 1 One-pot RAFT synthesis of amphiphilic mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 block copolymers. Reagents and conditions:
a. DCC, DMAP, 16 h, ambient temperature. Solvent: XvO: CH2Cl2. XvNH: THF; b. MHP (CTA), VA-044, EtOH/H2O, 70 °C. c. XvO: mPEGA12a macro-
CTA, ACH monomer, VA-044, EtOH/H2O, 70 °C; XvNH: mPEGA12b macro-CTA, CHB monomer, VA-044, EtOH/H2O, 70 °C.
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thus the polymerisation rate (Rp), of vinyl monomers,
40 which
is critical for eﬃcient in situ RAFT synthesis of multiblock
copolymers,18 whilst EtOH was required to solubilise the mono-
mers ACH (2) and CHB (3), and the (methyl 2-((((2hydroxy-
ethyl)thio)carbonothioyl)thio)propanoate), (MHP) chain-
transfer agent. The latter was chosen due to the higher hydro-
lytic stability of trithiocarbonates compared to other suitable
CTAs – e.g. dithioesters – and their ability to minimise initial
rate retardation sometimes observed in RAFT polymeris-
ations.41 In the one-pot protocol optimised in this work a
macro-CTA was first synthetised using commercially available
poly[ethylene glycol(480)]methyl ether acrylate, mPEGA(480)
and 2,2′-azobis[2-(2-imidazolin-2-yl)propane]dihydrochloride
(VA-044) as the water soluble initiator [I], at 70 °C (Scheme 1).
VA-044 is characterised by a high decomposition rate (t1/2 2 h
at 70 °C), which again is key to speeding up the polymerisation
without losing the chain livingness.32,33 mPEGA(480) was
chosen for the synthesis of the first hydrophilic block because
of its aqueous solubility, biocompatibility and ability to gen-
erate polymers with prolonged plasma half-life and low
immunogenicity.42–44 After an initial series of experiments
required to identify suitable reaction conditions (i.e. monomer
concentration and [CTA]/[I] molar ratio) which would allow to
reach near-quantitative monomer conversion whilst retaining
chain-end fidelity, a [CTA]/[I] ratio of 250 : 1 and a monomer
concentration of 2.0 M were chosen. The degree of polymeris-
ation (DP) for the p(mPEGA) macro-CTA was targeted to 12.
After 2 h the reaction reached a monomer conversion >95%, as
assessed by 1H NMR, by comparing the decrease of the signal
for the vinyl proton at ∼5.96 ppm to that of the mPEG terminal
methoxy group at 3.24 ppm (see ESI, Fig. S9 and S10†). SEC
analysis of the macro-CTA (mPEG12a, mPEG12b, Table 1 and
Fig. 1), using DMF + 0.1% LiBr as the mobile phase showed
unimodal, symmetric, and narrow molecular weight distri-
butions (Đ < 1.13), with Mn, SEC in good agreement with the
theoretical one (Table 1, polymers 4 and 5). Two diﬀerent
macro-CTAs, mPEGA12a and mPEG12b, both with DP = 12 were
synthesised and directly utilised without isolation or purifi-
cation for the synthesis of mPEGA12a-b-ACH36 (6) and
mPEGA12b-b-CHB36 (7), respectively. Importantly, both reac-
tions led to the desired mPEGA12 macro-CTAs with near-quan-
titative monomer conversion, thus validating the reproducibil-
ity of this process. Both acrylate ACH (2) and acrylamide CHB
(3) monomers have limited solubility in water, hence for the
second polymerisation step they were first dissolved in EtOH,
then the resulting solutions were diluted with water to a final
EtOH/water volume ratio of 2 : 1. To ensure full monomer con-
version in the one-pot RAFT with higher EtOH content, a
larger amount of radical intitiator was required;33 in this work
for the second block a [macro-CTA]/[I] ratio of 150 : 1 was
initially chosen in both cases. A DP of 34 for both ACH and
CHB was targeted, to provide final copolymers with a hydro-
philic block weight fraction ( f = 35% ± 10%)45 suitable for self-
assembling into vesicles.2 Indeed, when considering the Mn
provided by 1H NMR analysis the calculated f values were 0.358
and 0.357 for mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36,
respectively.
Following the addition of ACH (2) or CHB (3) monomers
and VA-044 radical initiator, a monomer conversion of 80–90%
was observed after 2 hours. Additional radical initiator was
necessary to achieve >95% of monomer conversion (Table 1,
polymer 6 and 7, see ESI Fig. S11 and S12†), resulting in a
final [macro-CTA]/[I] ratio of 1 : 50 or 1 : 30 for mPEGA12a-b-
ACH36 and mPEGA12b-b-CHB36, respectively. A possible expla-
nation for this is that the second block grown here is longer
than most of those prepared by Perrier and coworkers for
which near-full conversion could be achieved under the con-
ditions reported,18,27,32–34 although other side-processes – e.g.
very minimal H transfer from ACH (2) or CHB (3) monomers –
cannot in theory be ruled out at this stage. Nevertheless, pleas-
ingly, SEC analysis (Table 1 and Fig. 1) showed that very well
defined block-copolymers with a final Đ of 1.18 (mPEGA12a-b-
ACH36) and 1.17 (mPEGA12b-b-CHB36), were synthesised indi-
cating good control over the polymerisation process. The DP of
the second block was determined by 1H NMR, by comparing
the integral of the OCH3 signal of mPEGA repeating units in
the hydrophilic block at 3.24 ppm, with that of the aromatic
proton of ACH and CHB repeating units at 6.93 ppm (ESI,
Fig. S11 and S12†). A DPNMR of 36 was found for the second
block of both mPEGA12a-b-ACH36 (6), and mPEGA12b-b-CHB36
(7), slightly higher than the expected 34. This can be explained
considering that a minimal amount of mPEGA12 macro-CTA
was withdrawn at the end of the first polymerisation step for
1H NMR and SEC analysis, thus very marginally increasing the
monomer : macro-CTA molar ratio.
Polymersomes in-line assembly, drug loading and
characterization
At the end of the polymerisation runs the reaction mixtures
were diluted with additional EtOH to a polymer concentration
of 35 mg mL−1 (total volume 37 mL) to facilitate the sub-
sequent manipulations and assembly of mPEGA12a-b-ACH36 (6)
and mPEGA12b-b-CHB36 (7) into their corresponding polymer-
somes. The resulting solutions were kept at 40 °C to ensure
Fig. 1 SEC traces and 1H NMR spectra (DMSO-d6) of non-puriﬁed
mPEGA12 macro-CTA and ﬁnal block copolymers for A. mPEGA12a-b-
ACH36 (6), and B. mPEGA12b-b-CHB36 (7).
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full polymer solubilisation and reduced viscosity of the
polymer solutions. To assemble non drug-loaded vesicles
these solutions were directly cannulated under stirring into DI
water (final polymer concentration of 1 mg mL−1).
Polymersomes assembly was confirmed by DLS analysis of
the water/ethanol mixture immediately after the cannulation
process. DLS traces showed the presence of nanoassemblies
with an average diameter of 136 ± 2 nm and 89 ± 11 nm for
mPEGA12a-b-ACH36, and mPEGA12b-b-CHB36, respectively.
Ethanol was removed by either dialysis or slow evaporation
at room temperature, and the resulting assemblies were
characterised by dynamic light scattering (DLS) and trans-
mission electron microscopy (TEM). The in line polymersomes
assembly process led to homogeneous dispersions of poly-
meric vesicles in water, (Fig. 2A), with hydrodynamic diameters
estimated by DLS of 122 ± 20 nm or 41 ± 0.18 nm, for
mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7), respect-
ively, with narrow PDI (<0.23). Similar results in terms of
vesicle size and polydispersity were obtained regardless of the
method used for removal of traces of ethanol in the polymer-
somes suspension (data not shown).
To test the eﬃciency of the in-line process in assembling
well-defined vesicles, conventional nanoprecipitation of purified
mPEGA12a-b-ACH36 (6) and mPEGA12b-b-CHB36 (7) was also per-
formed. Accordingly, polymers were dissolved in DMSO (5.0 mg
mL−1) and water was added dropwise to the resulting solution
until a 1.0 mg mL−1 concentration was reached.
This procedure led to the formation of very similar size vesi-
cles in the case of mPEGA12a-b-ACH36 (122 ± 9 nm), but larger
assemblies in the case of mPEGA12b-b-CHB36 (172 ± 2 nm ESI,
Fig. S13†), a diﬀerence that could be ascribed to the diﬀerent
procedures and conditions used for their assembly.46
Analysis of the TEM images performed (ESI Fig. S14 and
S15†) on polymersomes prepared via the in-line procedure and
stained with 3% uranyl acetate solution gave results consistent
with the size estimated by DLS for both mPEGA12a-b-ACH36,
with an average core diameter of 126 ± 75 nm, and mPEGA12b-
b-CHB36 (44 ± 5 nm).
To gain further insight into the morphology of these vesi-
cles in solution, mPEGA12a-b-ACH36 and mPEGA12a-b-CHB36
polymersomes were analysed by AFM in PeakForce tapping
mode (Fig. 3). A major advantage of this method is that the
sample can be imaged in solution, thus obtaining a more rea-
listic representation of the vesicles morphology in comparison
to microscopy techniques performed on dry samples (i.e.
TEM). Furthermore, the use of tapping instead of contact
mode avoid the flattening caused by the pressure exterted,
allowing a more accurate estimation of vesicle size and three-
dimensional shape.
Immobilisation of the polymersomes on the mica surface, a
pre-requisite to perform the analysis, was achieved by electro-
static interactions.47 As described by Li et al.,48 negatively
charged polymers can be easily immobilized on a mica
Fig. 2 Characterisation of in-line assembled mPEGA12a-b-ACH36 and
mPEGA12b-b-CHB36 polymersomes (A) DLS analysis of one representa-
tive sample. Size shown refers to distribution of hydrodynamic diameter
measured by DLS at 173° in water, at 25 °C. Size (nm) is reported as
z-average mean. N = 2. (B) TEM images of polymersomes stained with
3% uranyl acetate solution.
Fig. 3 Representative examples of vesicle morphology as seen by AFM
analysis of polymersomes prepared from 1. mPEGA12a-b-ACH36 and 2.
mPEGA12a-b-CHB36. A. AFM height image of polymersomes adsorbed
on a mica surface in PBS solution (0.50 mg mL−1); B. The corresponding
topographic 3D rendered image showing the distribution of polymer-
some heights; C. List of the mean height, mean area and mean diameter
of adsorbed polymersomes at positions a–e or 1–4. D. Arrows highlight
some of the collapsed vesicle structures observed during these
measurements.
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surface, also negatively charged, via electrostatic interaction
mediated by Mg2+.
Our previous studies35 showed that at physiological con-
ditions (pH 7.4) polymers containing 3-chloro-4-hydroxybenzo-
ate repeating units are negatively charged due to the deproto-
nation of part of their aromatic alcohol pendant groups.
Accordingly, 1.0 mg mL−1 polymersome suspensions were pre-
pared by nanoprecipitation in PBS buﬀer. The average sizes
detected were around 80 nm for mPEGA12a-b-ACH36 and 45 nm
for mPEGA12a-b-CHB36 (Fig. 3). The height of both polymeric
aggregates was found to be around 14–17 nm, thus smaller
than their diameter, which can be ascribed to a partial col-
lapse of their hollow structure, thus confirming their vesicular
morphology.49 Partially collapsed structures with typical
‘deflated’ balloon’ morphology could also be visualized (Fig. 3,
insert 1D), thus further confirming the vesicular nature of
these supramolecular assemblies.
Larger sizes were estimated by DLS analysis of the polymer-
somes in PBS (170 and 70 nm for mPEGA12a-b-ACH36 and
mPEGA12a-b-CHB36, respectively, Fig. S16 ESI†) in comparison
to those observed by AFM analysis. It has already been shown
that the vesicles hydrodynamic diameter estimated by DLS can
be larger than the geometrical diameter because of the
hydration layer of the polymer shell.50 Liang et al. have dis-
cussed a similar discrepancy observed when analysing EggPC/
cholesterol vesicles by both DLS and AFM and ascribed it to a
potential partial fragmentation of larger vesicle upon adsorp-
tion on mica, and/or the intrinsic higher sensitivity of DLS for
larger vesicle, which results in an overestimation of the mean
hydrodynamic diameter.51 The latter phenomenon has also
been described when AgNPs53 and polystyrene nanoparticles52
were utilised to compare these two analytical techniques.
To establish an automated and robust process to generate
polymersomes reproducibly and with very low polydispersity, a
microfluidic system was then engineered (Fig. 4). Indeed,
microfluidic strategies have been successfully employed to fab-
ricate soft micro- and nano-assemblies54,55 To this aim,
polytetrafluoroethylene (PTFE) tubing were secured with
gaskets inside the screw-tight caps of a 3-way connector. An
ethanolic solution (12 mg mL−1) of mPEGA12b-b-CHB36 main-
tained at 50 °C was injected via pump syringe at 10 µL min−1
(Flow A, Fig. 4) into a junction where DI water entered via
another ID 0.5 mm tube at a flow rate of 120 µL min−1 (Flow B,
Fig. 4). The mixed liquids (Flow C, Fig. 4) exited the junction
via an ID 1 mm tube and were collected for size analysis. A
range of A and B flow rates were tested in preliminary experi-
ments to optimize the solvent mixing inside the connector.
Polymersomes were obtained with this methodology at a rate
of 0.12 mg min−1, and were analysed by DLS before and after
ethanol evaporation.
The average size in the two cases was found to be very
similar, with a diameter for the vesicles in pure water of 37 ±
7 nm and a PDI of 0.15 ± 0.04. One of the major advantages
oﬀered by this technique is the possibility of finely tuning the
ratio of the two solvents in the device by independently modi-
fying the solvent flow rates via syringe pumps, and to mini-
mise the use of organic solvent required to induce the for-
mation of homogeneous vesicles. The accurate control of the
flow rate also resulted in very consistent batch to batch repro-
ducibility (Fig. S17 ESI†), in a process that could easily be
scaled up for large scale production.
Finally, the eﬃciency of the in-line assembly process to
incorporate hydrophilic and hydrophobic drugs within the
vesicle structures was then investigated. In general, thera-
peutics are entrapped within polymersomes either during
their preparation, or by introduction of drug molecules into
pre-formed vesicles.21 For the latter, injection56 or electropora-
tion57 techniques are typically employed. In the former case,
hydrophobic molecules can be incorporated into polymeric
films utilised to prepare polymersomes, whilst hydrophilic
drugs can be introduced into the aqueous phase used to rehy-
drate these films.58 Other commonly used techniques include
solvent exchange mediated encapsulation,59 and the use of
microfluidics to load small molecules or proteins while
forming vesicles.60
In this present study two model molecules, terbinafine, a
hydrophobic antifungal drug which is very poorly soluble in
water in its free base form (<2 µg mL−1, as assessed by
RP-HPLC, data not shown), and hydrophilic cyanocobalamine
(Vit B12, solubility in water ca. 10–11 mg mL−1)61 were chosen
as model drugs for incorporation within vesicle lipophilic
membrane and aqueous lumen, respectively. In addition to its
hydrophobic nature, terbinafine was chosen due to the pres-
ence of a tertiary alkyl amine in its structure, which by
forming ionic pairs with the weakly acidic 3-chloro-4-hydroxy-
benzoic ester repeating units (pKa 7–7.5)
36 in the hydrophobic
blocks of mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 could
lead to more eﬃcient drug entrapment. This phenomenon was
observed in our previous studies using analogous block co-
polymers, where we utilised tamoxifen, a hydrophobic drug
with a basic tertiary amine group, which gave drug loading
capacity as high as 18%.36 In typical experiments, at the end of
the polymerisation reaction an ethanolic solution of terbina-
fine free base (35 mg mL−1) was added via syringe to the poly-
merisation mixture to give a 10% w/w drug/polymer solution,
at 40 °C. Cyanocobalamine was dissolved in the aqueous
medium used for the subsequent assembly of mPEGA12a-
b-ACH36 (6) and mPEGA12b-b-CHB36 (7)-based polymersomes,
Fig. 4 Automated assembly of mPEGA12b-b-CHB36 polymersomes:
schematic representation of the microﬂuidic device utilised in this study.
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again in a 10% w/w drug/polymer ratio. The polymer–terbina-
fine solutions were then cannulated into water–cyanocobala-
mine solutions, to generate the desired drug-loaded
mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36-based polymer-
somes. As observed in previous experiments, rapid self-assem-
bly into vesicles with no visible precipitation was observed,
suggesting that the method was robust, and that rapid for-
mation of polymersomes under these conditions was not nega-
tively aﬀected by the presence of loaded molecules. The excess
of cyanocobalamine was removed by dialysis against water
using a 6–8 kDa MWCO membrane, while traces of unen-
trapped terbinafine were subsequently removed after the dialy-
sis step by centrifugation, followed by filtration through a
0.45 µm filter. Drug loading was quantified by RP-HPLC (see
ESI†) on the resulting purified vesicles.
Both mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36, block
copolymers displayed a higher cyanocobalamine loading
capacity (LC) (Table 2). Interestingly, the acrylamide based
polymer mPEGA12b-b-CHB36 showed better drug encapsulation
for both the hydrophilic cyanocobalamine and lipophilic terbi-
nafine. Vesicles were analysed by DLS (Fig. 5) to investigate
how drug loading aﬀected their size and size distribution. As
we observed earlier with similar polymers,36 loaded polymer-
somes showed a smaller hydrodynamic radius than the empty
assemblies, decreasing to ∼72 nm for mPEGA12a-b-ACH36
while an increase in size to ∼80 nm was observed for
mPEGA12b-b-CHB36, as assessed by DLS analysis.
One possible explanation for this phenomenon is a
diﬀerent membrane packing caused by the presence of terbi-
nafine and potential ion pairing between the drug and the
weakly acidic 3-chloro-4-hydroxybenzoate of ACH and 3-chloro-
4-hydroxybenzamide of CHB polymer repeating units. The
observed high entrapment eﬃciency of cyanocobalamine may
be due, at least in part, to additional electrostatic interactions
between the partially deprotonated 3-chloro-4-hydroxybenzo-
ate/benzamide repeating units and positively charged CoIII
centres.
Conclusions
In this study we devised an in line synthetic/assembly strategy
which enables facile engineering of drug-loaded polymer-
somes in only a few hours, starting from acrylate/acrylamide
monomers. Using Perrier’s one-pot multiple chain extension
RAFT polymerisation strategy, amphiphilic mPEGA12a-b-ACH36
and mPEGA12b-b-CHB36 copolymers could be prepared with
narrow molecular weight distributions at very high monomer
conversion. Reaction conditions – concentration of monomers,
CTA : radical initiator molar ratio, nature of the reaction
solvent – were optimised to attain good control over the poly-
merisation process and to avoid intrinsically ineﬃcient purifi-
cation of reaction intermediates. Importantly, the process was
developed using ethanol : water as the reaction medium, in
view of a potential application of this process in biological/bio-
medical settings. The final reaction mixtures could then be
directly utilised to assemble well defined polymeric vesicles
incorporating both model hydrophilic and hydrophobic drugs
in the nanocarriers aqueous lumen and hydrophobic mem-
brane, respectively.
Similarly to click techniques where sub-families of chemi-
cal reactions are selected based on a range of favourable fea-
tures, and PISA, where monomers and macromolecular para-
meters are chosen to direct supramolecular assembly, our
results suggest that when appropriate reagents and conditions
are utilised, in line processes could become a viable general
route for eﬃcient, scaleable and cost-eﬀective assembly of
polymersome nanovectors.
Data access statement
All raw data created during this research are openly available
from the corresponding author (giuseppe.mantovani@notting-
ham.ac.uk) and at the University of Nottingham Research Data
Management Repository (https://rdmc.nottingham.ac.uk/) and
all analysed data supporting this study are provided as ESI†
accompanying this paper.
Table 2 Drug loading on vesicles (Loading Capacity – LC) and % rela-
tive loading (Encapsulation Eﬃciency – EE) of mPEGA12a-b-ACH36 and
mPEGA12b-b-CHB36 polymersomes using cyanocobalamin and terbi-
naﬁne as model drugs
mPEGA12a-b-ACH36 mPEGA12b-b-CHB36
Drug/pol. wt%a 10 10
LCcyanocobalamin 3.9 ± 0.4 6.0 ± 0.1
EEcyanocobalamin 38.7 ± 3.9 51.9 ± 1.0
LCTerbinafine 2.47 ± 0.03 4.7 ± 2.0
EETerbinafine 24.7 ± 0.28 46.6 ± 20.4
a In the reaction feed before assembly into polymersomes.
Fig. 5 (A) Loaded polymersomes (1.0 mg mL−1) size distributions of
hydrodynamic diameter measured by DLS at 173° in water at 25 °C. Size
(nm) is reported as z-average; (B) terbinaﬁne/cyanocobalamine-loaded
mPEGA12a-b-ACH36 and mPEGA12b-b-CHB36 polymersomes.
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